To date, five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib and lorlatinib) have been approved by the US Food and Drug Administration for treatment of advanced NSCLC harbouring ALK aberrations.5 Approved ALK inhibitor formulations have less frequent dosing schedules than TSR-011 at Q8h. The gene discussed is ALK; the disease is non-small cell lung carcinoma.